New blood test could spot liver cancer sooner
NCT ID NCT07265271
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This study aims to create a simple blood test to find liver cancer at an early, more treatable stage. Researchers will analyze genetic material in the blood of 600 adults, including those with liver cancer, chronic liver disease, and healthy volunteers. The goal is to improve early detection and save lives.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 600 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2025
- Expected to finish
-
Jun 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Individuals who were diagnosed with hepatocellular carcinoma. Individuals who were diagnosed with chronic liver disease Healthy donors
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults aged 18 to 100 years. * A histologically confirmed diagnosis of hepatocellular carcinoma. * A clinically diagnosed as chronic liver disease, including chronic hepatitis or liver cirrhosis, without evidence of hepatocellular carcinoma. * Healthy volunteers without known liver disease or malignancy. * Received standard diagnostic and staging procedures as per local guidelines * Availability of blood or other biospecimens. * Ability to provide written informed consent. Exclusion Criteria: * Lack of or inability to provide informed consent * History of other active malignancies within the past 5 years * Previous liver transplantation * Severe systemic infection or inflammatory disease at the time of enrollment * Inadequate sample quality or quantity
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic liver disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can two immunotherapy drugs make liver tumors more vulnerable to surgery?
- Saline barrier lets heat target liver tumors near the diaphragm
- Can a new PET tracer spot liver cancer more clearly?
- Can a smart drug starve liver tumors without harming healthy tissue?
- Liver size may hold key to immunotherapy response
- Can a new model forecast liver cancer in hepatitis b?